Public Citizen Report: FDA Looked the Other Way on Unapproved Peptides (21 November 2026)

Public Citizen, the US consumer advocacy group, published a report on 19 November 2026 titled “Asleep at the Vial: FDA Looked the Other Way as Unapproved Peptide Sales Boomed”. Written by Peter Whoriskey, research director of its Health Research Group, it argues that the FDA had already stopped policing unapproved peptides long before HHS announced its October policy on compounding six of them.
Below: what the report found, how it connects to the HHS policy, and what it means for laboratories that buy research-use-only peptides.
What the Public Citizen report found
- More than 150 FDA warning letters went to companies marketing unapproved substances since the start of the second Trump administration. The report says only one concerned a seller of one of the six peptides now covered by HHS, and that company had already agreed to shut down for other reasons.
- At least 11 companies that received FDA warnings for selling unauthorized GLP-1 weight-loss drugs also sold at least one of the six peptides; the warning letters did not mention the peptides.
- Citing blockchain analytics firm TRM Labs, the report says about 100 of the more than 200 companies found selling fentanyl precursors also sold peptides such as BPC-157, TB-500 and Epitalon.
- Past enforcement did happen: one compounding company agreed to forfeit $1,788,906.82 tied to its 2019 peptide sales, and in July 2026 the owner of a peptide company was sentenced to 70 months in prison.
- The report concludes that enforcement against unapproved peptides “ground to a halt” in 2025, and that the October 2026 HHS policy formalised an approach the FDA had already taken.
Our running list of letters sent to peptide sellers: FDA peptide warning letters.
How the report connects to the HHS peptide policy
In late October 2026 HHS announced an interim enforcement discretion policy for 503A pharmacies compounding six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The report points out that FDA’s Pharmacy Compounding Advisory Committee voted in July 2026 to recommend them for the 503A bulks list, while FDA staff scientists had recommended against each one, citing limited evidence. It quotes HHS Secretary Robert F. Kennedy Jr.: “Americans are going to be buying these anyway.”
Background on the policy: the HHS peptide compounding policy, the comment period that closed on 13 November, and Hims & Hers and Noom entering the market.
What the report does and does not say
| Point | What the report says | What it does not say |
|---|---|---|
| FDA enforcement | Largely stopped for peptides in 2025 | That peptides are now approved or legal for human use |
| HHS policy | Formalised an existing hands-off approach | That research-use-only sales are covered (they are not) |
| Supply chain | Overlap between peptide and fentanyl-precursor sellers | That every peptide seller is part of that overlap |
| Testing | Independent testers such as Finnrick and Janoshik publish results | That any supplier is safe for human use |
What it means for research labs
If regulators are not checking the market, the burden of checking falls on the buyer. For laboratory work that means:
- Lot-matched COAs: the lot number on the vial must appear on the certificate. Guide: how to verify a peptide COA.
- Identity and quantity: mass-spectrometry identity and measured net content, not only an HPLC purity figure. See HPLC vs mass spec.
- No human-use marketing: suppliers that make dosing or health claims are the ones that attract warning letters. Our criteria: how we verify suppliers.
- Legal status by country: are peptides legal?
What to watch next
- Whether HHS finalises, changes or withdraws the interim policy after reviewing public comments.
- FDA’s formal rulemaking on the 503A bulks list for the six peptides.
- Any return of FDA or DOJ enforcement against sellers making human-use claims.
- Further reports from Public Citizen’s Health Research Group, which also published on unapproved retatrutide products in June 2026.
Frequently asked questions
A report by Peter Whoriskey, research director of Public Citizen’s Health Research Group, dated 19 November 2026. Its full title is “Asleep at the Vial: FDA Looked the Other Way as Unapproved Peptide Sales Boomed”. It argues that FDA enforcement against unapproved peptides had largely stopped before HHS announced its October 2026 compounding policy.
More than 150 warning letters to companies marketing unapproved substances since the start of the second Trump administration. According to the report, only one went to a company selling one of the six peptides in the HHS policy, and that company had already agreed to shut down for other reasons.
The six peptides covered by the HHS interim enforcement discretion policy: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The report notes that FDA staff scientists had recommended against adding each of them to the 503A bulks list.
No. It is an advocacy report, not a rule. Research peptides remain unapproved and are sold for laboratory research only; the HHS policy covers only patient-specific compounding by 503A pharmacies under ten conditions.
That weak enforcement does not mean quality is checked by anyone. Labs should rely on lot-matched certificates of analysis from named laboratories, identity testing by mass spectrometry and measured net content, and should avoid suppliers that make human-use claims.
Sources
- Public Citizen: Asleep at the Vial (report page)
- Public Citizen: Asleep at the Vial, full report PDF (19 Nov 2026)
- Healio: HHS further loosens restrictions for several peptides (29 Oct 2026)
- Holland & Knight: HHS interim enforcement discretion policy (Nov 2026)
- RAPS: HHS will permit compounding of six peptides (29 Oct 2026)
- Public Citizen: unapproved retatrutide products (16 Jun 2026)
Checked 21 November 2026. Peptides in Lab is an independent education site. For laboratory research use only; not for human or veterinary use.
An independent reference for researchers in the US, UK and EU: compound profiles, lab tools and supplier checks.
For research and educational purposes only. Compounds described here are sold by third parties for laboratory research and are not approved for human or veterinary use. We do not provide dosing or treatment information. Some links earn us a commission at no cost to you. © 2026 Peptides in Lab.
Deal of the week50% off research peptides
Code IZBA50OFF at Ascension Peptides (US).
- Lumin:
IZBA1010% off (US) - Bench Grade:
IZBA+10% first order (US) - PX1 Research:
59A4F18915% off (US) - Simms:
IZBA07210% first order (US) - CertaPeptides:
AFF-IZBATAZEEM10% off (EU/UK)
Get 50% off now →See all codes and pricesAd · affiliate link · Research use only
